CollPlant Biotechnologies Ltd.

CLGN • Biotechnology

$3.82

▼ -0.06 (-1.55%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$5.51M

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Nivel de deuda manejable · 0.47Liquidez saludable · 2.53Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 2 oct 2026, 12:08 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$3.82

Change-1.55%

Shares Out1.44M

Market Cap$5.51M

Enterprise Value$3.45M

52W Range2.64 - 26.80

Beta0.74

P/E-0.44

P/S17.33

P/B1.87

P/FCF-0.47

EV/Sales10.86

Price$3.82

Change-1.55%

Shares Out1.44M

Market Cap$5.51M

Enterprise Value$3.45M

52W Range2.64 - 26.80

Beta0.74

P/E-0.44

P/S17.33

P/B1.87

P/FCF-0.47

EV/Sales10.86

EV/EBITDA-0.30

EV/FCF-0.30

Earnings Yield-227.06%

FCF Yield-212.33%

Dividend Yield0.00%

Gross Margin26.32%

Oper. Margin-4.84%

Profit Margin-4.85%

Debt/Eq0.47

Current Ratio2.53

Quick Ratio2.31

Target$12.50

Target Upside227.23%

Target Median$12.50

Target Range11.00 - 14.00

Volume26.20K

Avg Volume242.16K

EPS Surprise0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

74/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

62/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.47Liquidez saludable · 2.53Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

CLGN

Analyst sentiment

Based on 5 analyst votes · 2026-10-20

90/100

Bullish

Hold

Bearish

Precio objetivo

2026-10-02

Bajo

$11.00

Promedio

$12.50

Mediana

$12.50

Alto

$14.00

Resumen de la compañía

IPO: 1/31/2018

Industria: Biotechnology

P/B i: 1.87

Deuda / Patrimonio i: 0.47

Margen operativo: -484.31%

Margen neto: -484.56%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.47

Ratio corriente: 2.53

Ratio rápido: 2.31

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Abelis Bar Berta

Transacción: 09/03/2026

COMPRA

Cambio

+201,141

Precio

Not reported

Presentación

09/08/2026

Tipo

COMPRA

Rotem Eran

Transacción: 09/03/2026

COMPRA

Cambio

+510,372

Precio

Not reported

Presentación

09/08/2026

Tipo

COMPRA

Evans Hugh M

Transacción: 03/18/2026

OTRO

Cambio

Precio

Not reported

Presentación

04/27/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Abelis Bar Berta	COMPRA	+201,141	Not reported	09/03/2026	09/08/2026
Rotem Eran	COMPRA	+510,372	Not reported	09/03/2026	09/08/2026
Evans Hugh M	OTRO	0	Not reported	03/18/2026	04/27/2026
Evans Hugh M	OTRO	0	Not reported	03/18/2026	04/27/2026
Evans Hugh M	OTRO	+24,000	$6.39	05/02/2023	04/27/2026
Tal Yehiel	OTRO	0	Not reported	03/19/2026	03/19/2026
Tal Yehiel	OTRO	0	Not reported	03/19/2026	03/19/2026
Tal Yehiel	OTRO	+100,000	$6.39	05/02/2023	03/19/2026
Tal Yehiel	OTRO	+37,800	$4.02	05/18/2020	03/19/2026
Rotem Eran	OTRO	0	Not reported	03/18/2026	03/18/2026
Fahimipoor Oren	OTRO	0	Not reported	03/18/2026	03/18/2026
Bensimon Philippe	OTRO	0	Not reported	03/18/2026	03/18/2026
Bensimon Philippe	OTRO	0	Not reported	03/18/2026	03/18/2026
Seror Jasmine	OTRO	0	Not reported	03/18/2026	03/18/2026
Abelis Bar Berta	OTRO	0	Not reported	03/18/2026	03/18/2026
Bagley Bowman	OTRO	0	Not reported	03/18/2026	03/18/2026
Havron Avraham	OTRO	0	Not reported	03/18/2026	03/18/2026
Penn Elan	OTRO	0	Not reported	03/18/2026	03/18/2026
Lask Alisa	OTRO	0	Not reported	03/18/2026	03/18/2026
Fahimipoor Oren	OTRO	+50,000	$7.50	03/28/2024	03/18/2026

Sobre la compañía

CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.

Fuente - Link

Competidores

CVKD ENLV KLTO MTVA NRSN NRXS RLYB SONN TAOX XCUR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT

Transaction Led Primarily by Existing Investors to Accelerate LightSolver's Laser-Based Supercomputing Development REHOVOT, Israel, Oct. 9, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), an innovative technology company operating at the intersection of deep-tech photonic computing and biotechnology today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 989,301 of the Company's ordinary shares (or ordinary share equivalents in lieu thereof) and unregistered warrants to purchase up to 1,483,952 ordinary shares in a private placement at a combined purchase price of $3.74 per ordinary share and accompanying warrants (or $3.7399 per ordinary share equivalent and accompanying warrants). The private placement, which is comprised primarily of the Company's existing investors, reflects confidence in CollPlant's expanded strategic vision and its execution capabilities in deep-tech photonic computing.

PRNewsWire

LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations

CollPlant Advances its Photonic Computing Strategy Through LightSolver's Growing IP Portfolio REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary, LightSolver, has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for an invention that significantly expands the capabilities of its all-optical, laser-based computing platform.

PRNewsWire

Critical Contrast: CollPlant Biotechnologies (NASDAQ:CLGN) & CareDx (NASDAQ:CDNA)

CareDx (NASDAQ: CDNA - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings. Risk and Volatility CareDx has a beta of 2.38,

Defense World

COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Strategic Expansion into Photonic Computing via LightSolver Acquisition Diversifies Technology Portfolio Alongside Continued Innovations in Regenerative Medicine REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), today announced financial results for the second quarter of 2026 and provided a corporate update.

PRNewsWire

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) Stock Short Interest Declines 60.2%

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ: CLGN - Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 52,237 shares, a decline of 60.2% from the August 31st total of 131,118 shares. Based on an average daily trading volume,

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-29	-0.2374	-0.23	0.0074
2026-03-26	-0.2977	-0.67	-0.3723
2025-11-26	0.38	-0.27	-0.65
2025-08-20	-0.1	-0.28	-0.18
2025-05-28	-0.37	-0.13	0.24
2025-03-26	-0.42	-0.34	0.08
2024-11-27	-0.28	-0.38	-0.1
2024-08-20	-0.35	-0.37	-0.02
2024-05-29	-0.35	-0.37	-0.02
2024-04-04	0.24	-0.42	-0.66
2023-11-29	-0.13	-0.38	-0.25
2023-08-24	0.015	0.49	0.475